Mineralys Therapeutics (NASDAQ:MLYS) CFO Adam Scott Levy Sells 10,758 Shares

by · The Markets Daily

Mineralys Therapeutics, Inc. (NASDAQ:MLYS – Get Free Report) CFO Adam Scott Levy sold 10,758 shares of Mineralys Therapeutics stock in a transaction dated Monday, January 12th. The shares were sold at an average price of $32.14, for a total transaction of $345,762.12. Following the sale, the chief financial officer owned 8,638 shares of the company’s stock, valued at approximately $277,625.32. This represents a 55.47% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Adam Scott Levy also recently made the following trade(s):

  • On Tuesday, November 11th, Adam Scott Levy sold 119,524 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $44.88, for a total transaction of $5,364,237.12.

Mineralys Therapeutics Price Performance

MLYS stock traded down $0.04 during mid-day trading on Tuesday, reaching $32.94. The company had a trading volume of 2,027,806 shares, compared to its average volume of 1,344,631. Mineralys Therapeutics, Inc. has a fifty-two week low of $8.24 and a fifty-two week high of $47.65. The firm has a fifty day simple moving average of $38.74 and a 200 day simple moving average of $30.89.

Mineralys Therapeutics (NASDAQ:MLYS – Get Free Report) last released its quarterly earnings results on Monday, November 10th. The company reported ($0.52) EPS for the quarter, beating the consensus estimate of ($0.66) by $0.14. Analysts anticipate that Mineralys Therapeutics, Inc. will post -4.23 earnings per share for the current fiscal year.

Institutional Trading of Mineralys Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Smartleaf Asset Management LLC boosted its holdings in shares of Mineralys Therapeutics by 198.2% during the third quarter. Smartleaf Asset Management LLC now owns 1,017 shares of the company’s stock worth $40,000 after purchasing an additional 676 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Mineralys Therapeutics by 51.0% during the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,518 shares of the company’s stock worth $34,000 after purchasing an additional 850 shares during the period. Russell Investments Group Ltd. raised its holdings in Mineralys Therapeutics by 14,091.3% in the third quarter. Russell Investments Group Ltd. now owns 3,264 shares of the company’s stock valued at $124,000 after buying an additional 3,241 shares during the period. Ameritas Investment Partners Inc. lifted its position in Mineralys Therapeutics by 42.8% during the second quarter. Ameritas Investment Partners Inc. now owns 3,995 shares of the company’s stock valued at $54,000 after buying an additional 1,197 shares in the last quarter. Finally, Victory Capital Management Inc. purchased a new stake in Mineralys Therapeutics during the third quarter worth approximately $216,000. 84.46% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on MLYS shares. HC Wainwright raised their price objective on Mineralys Therapeutics from $52.00 to $56.00 and gave the company a “buy” rating in a research note on Wednesday, November 12th. Wells Fargo & Company lifted their target price on shares of Mineralys Therapeutics from $50.00 to $55.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 11th. Stifel Nicolaus raised their price objective on shares of Mineralys Therapeutics from $45.00 to $52.00 and gave the stock a “buy” rating in a research note on Friday, December 19th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Mineralys Therapeutics in a research note on Wednesday, October 8th. Six equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $47.43.

Read Our Latest Stock Analysis on Mineralys Therapeutics

Mineralys Therapeutics Company Profile

(Get Free Report)

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc and changed its name to Mineralys Therapeutics, Inc in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.

Featured Articles